Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park

- New donation to support new Life Sciences Center and strengthen BioWork program to increase North Carolina's talent pipeline in life science and biopharma manufacturing roles.
- Biogen also recently announced a manufacturing investment in its Research Triangle Park operations.
- Biogen is North Carolina's largest biotechnology employer with more than 1,500 employees and 400 skilled contractors across its Wake County and Durham County campuses.

Research Triangle Park, N.C. – October 9, 2025 – Biogen Inc. (Nasdaq: BIIB) is commemorating 30 years of manufacturing investment, innovation, workforce development and community partnership in North Carolina's Research Triangle Park (RTP). Today the company is celebrating its anniversary with a donation to expand its collaboration with Durham Technical Community College to train the next generation of life sciences workers. Earlier this summer, Biogen also announced a new investment of $2 billion in its RTP manufacturing facilities, including capabilities, infrastructure, and continued modernization of manufacturing technologies and controls.

"North Carolina is a global leader in life sciences, and Biogen has been at the heart of that story for three decades," said Josh Stein, Governor of North Carolina. "This new $2 billion investment means more innovation, more good-paying jobs, better health, and a stronger economy."

Today's pledge of $250,000 from Biogen and the Biogen Foundation to Durham Tech's new Life Sciences Center will fund a lab hall anchored by the BioWork Lab. The lab enables learners to earn manufacturing certification and transition directly into careers in biopharma manufacturing. In 2024, the company began offering Durham Tech's BioWork program in the Biogen CoLab. To date, approximately 50% of BioWork graduates from the CoLab partnership have been hired to work at Biogen. Biogen and Durham Tech aim to expand the current capacity of the program, with the goal to increase the number of graduates who are ready to step into critical manufacturing roles at Biogen and across the region. This partnership is part of a broader effort by Biogen to support local universities and industry consortiums in RTP to strengthen the life science talent pipeline.

"As the largest biotechnology employer in the state, we recognize how important it is to invest in the next generation of manufacturing and technical operations talent," said Nicole Murphy, Head of Pharmaceutical Operations and Technology. "Our highly skilled workforce has been the backbone of our exceptional operational success over the last three decades and we know firsthand how critical a strong talent pipeline is to ensure continued safe and reliable manufacturing of life-changing medicines for patients around the world. Through strong partnerships with North Carolina institutions and immersive experiences in our CoLab, we aim to open doors for students to thrive and drive the next wave of scientific breakthroughs."

North Carolina is seeing workforce demand in the life sciences accelerate. The state employs more than 32,000 people in biopharma manufacturing and is predicted to grow by 8,000 or more by the end of 2026, according to industry estimates[1]. The investment in the new Life Sciences Center

| More |

reflects Biogen's continued commitment to supporting the region's workforce and strengthening partnerships that help prepare local talent for careers in biotechnology.

"We can think of no better way to commemorate our decades of educational partnership in the Research Triangle Park community than with this important investment in our students," said J.B. Buxton, President of Durham Technical Community College. "Biogen has long been a vital part of the RTP innovation footprint, advancing the development and manufacturing of potentially life-saving therapies. This investment ensures that students here in our community have the skills and opportunities to step into these critical roles and keep RTP at the forefront of biomanufacturing in the U.S. and around the globe."

As one of the first biomanufacturing facilities in the state, Biogen has contributed to RTP's evolution into a global hub for life sciences. In July, the company announced plans to invest $2 billion in multiple factories and modalities across the company's two campuses in RTP. The company also expects its eighth facility in RTP to be running by the end of the year.

Biogen's RTP facilities produce complex, high-quality medicines for the U.S. and rest of the world, and have delivered more than 60 unique products across various factories to support both clinical and commercial portfolio patient needs. Biogen currently employs more than 1,500 employees and more than 400 skilled contractors in North Carolina.

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including relating to: Biogen's donation to Durham Tech and our aim to expand the Biogen CoLab program; our plan to invest in programs to support and expand the life sciences workforce in RTP; our investment in RTP manufacturing facilities and the expected timing of the operation of a new facility; the potential of our commercial business and pipeline programs; and the risk and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "outlook," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would" or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.

| More |

Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part.

We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this press release, including, among others, factors relating to: our substantial dependence on revenue from our products and other payments under licensing, collaboration, acquisition or divestiture agreements; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the drivers for growing our business; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology, including our incorporation of new technologies such as artificial intelligence into some of our processes; risks related to use of information technology systems and potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of our systems or those of connected and/or third-party systems; problems with our manufacturing capacity, including our ability to manufacture products efficiently or adequately address global bulk supply risks; risks relating to management, personnel and other organizational changes, including our ability to attracting, retaining and motivating qualified individuals; risks related to the failure to comply with current and new legal and regulatory

| More |

requirements, including judicial decisions, accounting standards, and tariff or trade restrictions; the risks of doing business internationally, including geopolitical tensions, acts of war and large-scale crises; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business, results of operations and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets to finance our present and future operations and business initiatives and obtain funding for such activities on favorable terms; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate and obligations in various jurisdictions in which we are subject to taxation; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

References:

1. North Carolina Biotechnology Center, 2023, *Window on the Workplace 2023: Workforce Training Needs for North Carolina’s Biopharma Manufacturing Industry*. Available at: WoW Report 2023 (22-145_LSED) SINGLE PAGE FINAL.pdf

###

MEDIA CONTACT(S):
Biogen
Madeleine Shin
+ 1 781 464 3260
public.affairs@biogen.com

INVESTOR CONTACT(S):
Biogen
Tim Power
+1 781 464 2442
IR@biogen.com